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ABSTRACT 
 From 1957 to 1962, Thalidomide was prescribed to pregnant women as an antiemetic and was 
later discovered to cause serious birth defects. Thalidomide is currently being prescribed to treat 
erythema nodosum leprosum and multiple melanoma, and is being considered for other anti-angiogenic 
applications. This is of concern, as the mechanisms by which thalidomide disrupts development remain 
largely unknown. This lack of knowledge is largely due to the absence of an appropriate model 
mammalian system. Traditional mammal models, such as rats and mice, are resistant to the teratogenic 
properties of thalidomide. We propose to develop the gray short-tailed opossum (Monodelphis 
domestica) as a novel mammalian to study thalidomide teratogenesis. In M. domestica we have 
successfully recreated most morphological defects found in human thalidomide victims. Through RNA 
sequencing, we have also identified two gene that may play a significant role in the mechanism of 
thalidomide induced birth defects.  
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INTRODUCTION 
 Thalidomide was originally marketed in 1957 as a non-barbiturate sedative. The drug’s mild side 
effects on the patient made it incredibly popular in the treatment of morning sickness. In 1959 
thalidomide was found to cause a wide spectrum of very serious birth defects. The drug was completely 
removed from the market by 1962. Thalidomide is estimated to be responsible for affecting birth 
defects in over 10,000 children in Germany alone (Dove, 2011). As thalidomide was sold in a large 
number of nations other than the United States, the total number of victims cannot be accurately 
estimated. The release of thalidomide into the market is widely considered to be the worst medical 
regulatory failure in history. Despite its sordid history, thalidomide reemerged on the market in 1965 as 
a treatment for erythema nodosum leprosum. In 1998 thalidomide also began to be used to help treat 
multiple myeloma, and other anti-angiogenic applications of the drug are being developed (Calabrese & 
Fleischer, 2000). Unfortunately, thalidomide’s revival has been accompanied by a second generation of 
children with thalidomide-induced birth defects. In fact, children continue to be born with thalidomide-
induced deformities; with at least 100 cases documented in Brazil between 2005 and 2010 (Crawford, 
2013).  
 Despite its long and devastating history, the teratogenic mechanisms of thalidomide remain 
poorly understood. This lack of knowledge and the early misuse of the drug are primarily due to a lack of 
an appropriate mammalian model study system for the impact of thalidomide on mammalian 
development. Traditional mammal models, such as rats and mice, are resistant to the teratogenic 
properties of thalidomide. Though susceptible, studies of rabbit and other primates are hampered by 
the number of affected embryos that can be obtained (Vargesson, 2009). Until now, this has left two 
other types of study systems: non-mammalian vertebrates and human cell cultures. Much of what is 
known about the mechanisms through which thalidomide causes limb deformations comes from 
research in non-mammalian vertebrates, such as chickens and zebrafish. Though fully vulnerable to 
thalidomide defects, wings and fins develop differently enough to severely limit what can be learned 
about the limb defect. Furthermore the window of thalidomide sensitivity is notably later in chickens 
than in mammals. Humans are susceptible to thalidomide induced limb defects from the time of the 
initial formation of the limb bud. In contrast, thalidomide susceptibility in chicken limbs does not begin 
until well after both limb buds are formed and the forelimb has enlarged significantly (Knobloch, 
Shaughnessy, & Rüther, 2007). Human cell cultures, most commonly human umbilical vein endothelial 
cells (HUVECS), are not subject to these cross taxa limitations. They have also been very useful in 
understanding the thalidomide’s effect on a cellular level. However they lack the developmental and 
2 
 
cross-tissue context which limits what can be learned about the mechanisms by which thalidomide 
generates limb deformities. 
 We propose to develop the gray short-tailed opossum (Monodelphis domestica) as a novel 
mammalian to study thalidomide teratogenesis. Unlike rodents, we show that opossums are vulnerable 
to thalidomide-induced limb deformities. Opossums are the first fully susceptible mammal for which 
affected embryos can be obtained in large numbers. Furthermore, M. domestica is a well-established 
study system for limb development and has a fully sequenced and well-annotated genome (Mikkelsen et 
al., 2007). M. domestica also displays a unique mode of limb development that makes it well suited for 
studying limb deformities. Specifically, M. domestica forelimbs grow at twice the rate of their hind limbs, 
which provides two temporal opportunities to study thalidomide-induced limb deformities (Doroba & 
Sears, 2010; Keyte & Smith, 2008). Here we show that M. domestica is an effective model organism to 
investigate the teratogenic impacts of thalidomide and, based on our research in M. domestica, propose 
a novel mechanism for thalidomide-induced digit reduction in mammals.  
Thalidomide Effects - Thalidomide was originally marketed as a non-barbiturate sedative. The 
adult side effects are mild and include: constipation, edema, hypocalcaemia, shortness of breath and 
peripheral neuropathy (Sekeres & List, 2006; Tseng, Pak, Washenik, Pomeranz, & Shupack, 1996). 
Thalidomide is currently only marketed for anti-angiogenic applications such as erythema nodosum 
leprosum and multiple myeloma. 
 However it is thalidomide’s teratogenic effects that have proved most catastrophic. Thalidomide 
birth defects are characterized by a very specific window of sensitivity. In humans, thalidomide birth 
defects have only been observed when the drug is administered between 20 and 36 days post-
fertilization. The most potent defects occur between 27-33 days post-fertilization (Lenz & Knapp, 1962). 
Treatment prior to day 20 has been shown to induce miscarriage in humans and is hypothesized to be 
caused by heat malformations (Miller & Strömland, 1999; Vargesson, 2009). Thalidomide treatment 
after the period of sensitivity has only been shown to increase the risk of autism and interfere with the 
angiogenesis of parts of the brain (Vargesson, 2013). The vast majority of thalidomide defects occur 
during the window of sensitivity.  
 The most recognizable defects caused by thalidomide are those impacting the limbs. The most 
common of these limb deformities is phocomelia of the upper limb. Phocomelia is the severe truncation 
of the limb, usually the more proximal elements, with fully formed distal elements such as the hand and 
digits. Other limb deformities have also been noted such as radial dysplasia, triphalangeal thumb, and 
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amelia(Miller & Strömland, 1999). Lower limb deformities are less common and usually only occur when 
upper limb deformities are present (Lenz & Knapp, 1962; Vargesson, 2013).  
 Non-limb thalidomide defects are diverse and variable. The most common of these are heart 
defects. These heart defects may be the cause of much of the thalidomide-induced embryonic death 
prior to 20 days in humans.  Liver hypoplasia, irregular vertebral spacing, shoulder and hip deformities 
are also used to diagnose thalidomide teratogenesis. Deafness and blindness have also been linked to a 
wide spectrum of thalidomide ear and eye defects. Many other less common thalidomide deformities 
occurring during the window of sensitivity have also been documented (Smithells & Newman, 1992; 
Vargesson, 2013). 
Dosage sensitivity - As thalidomide is water insoluble, it is given to humans in oral tablets. In 
other mammals, it is dissolved in dimethyl sulfoxide (DMSO) and delivered via gavage feeding or 
intraperitoneal injection. Thalidomide’s historical dosage varied widely, from a 25mg-400mg daily, 
though it could have been taken in greater amounts as it was available without a prescription in Japan 
and West Germany. Modern therapeutic doses range from as little as 50mg for multiple myeloma to as 
much as 400mg for erythema nodosum leprosum. Thalidomide is an extremely potent teratogen. A 
single 50mg dose of the drug was sufficient to cause miscarriage in humans (Lenz & Knapp, 1962) and 
the minimum teratogenic dosage has not been determined in utero. 50µg/mL has been demonstrated to 
be the minimal concentration to inhibit cell migration in endothelial cell culture (Tamilarasan et al., 
2006).  
Primary Binding - Thalidomide has two isomeric forms, R (+) and S (-). The S (-) is believed to be 
an effective sedative while the R (+) is believed to be responsible for the teratogenic effects. An 
enantiomeric stable version of the S(-) form has been demonstrated to be responsible for thalidomide’s 
anti-inflammatory and tumor suppressing activities (Jacques, Czarnik, Judge, Van der Ploeg, & DeWitt, 
2015). However, the teratogenic properties of this stabilized drug remain untested. Thalidomide is also 
known to form at least 20 metabolites, many of which can exert their own immunomodulatory, anti-
inflammatory, or anti-angiogenic function (Ando, Fuse, & Figg, 2002; Tseng et al., 1996). The variety of 
biologically active products make thalidomide a very difficult drug to study using biochemical 
approaches. 
 Only recently has the primary binding target of Thalidomide been identified as Cereblon 
(CRBN)(Ito et al., 2010). CRBN forms an E3 ubiquitin ligase with Damaged DNA Binding Protein 1 (DDB1) 
and Cullin 4A (Cul4A). Zebrafish CRBN mutants that reduce thalidomide binding affinity are not 
susceptible to thalidomide-induced limb defects. Human CRBN overexpression has also been 
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demonstrated to be sufficient to rescue thalidomide-induced birth defects in these in chickens (Fischer 
et al., 2014; Ito, Ando, & Handa, 2011; Ito et al., 2010). However, research in human cell lines has shown 
that natural thalidomide resistance is not imparted by mutations in either in either CRBN or DDB1 
(Thakurta et al., 2014). CRBN is also very well conserved across taxa and is ubiquitously expressed in 
opossum development(Ito et al., 2010).  These lines of evidence suggest that the CRNB complex is 
necessary but not sufficient to cause thalidomide-induced teratogenesis and is likely not the source of 
the species or tissue specific nature of the drug. Multiple non-exclusive mechanisms have been used to 
explain the downstream effects of thalidomide, such as angiogenic antagonization, free radical 
production, and fibroblast growth factor patterning disruptions (Ito et al., 2011; Knobloch & Rüther, 
2008; Vargesson, 2013). 
Anti-Angiogenic Properties - Thalidomide’s best studied function is as a powerful anti-
angiogenic. By inhibiting beta fibroblast growth factor (bFGF) and vascular endothelial growth factor 
(VEGF), thalidomide is able to inhibit blood vessel maturation or angiogenesis in all studied taxa 
(Kenyon, Browne, & D'amato, 1997). Thalidomide has been shown to reduce microvessel density and is 
being explored in a variety of therapeutic applications, such as the treatment of hereditary hemorrhagic 
telangiesctasia (Du et al., 2004; Lebrin et al., 2010). Though the connection between the primary CRBN 
binding and the anti-angiogenic effects remains unclear, much is still known about thalidomide 
phenotype. Key regulators of angiogenesis such as VEGF, IL-8, bFGF8 and members of the hedgehog 
signaling pathways have been shown to be significantly depleted with thalidomide treatment. 
Thalidomide does not appear to cause any major changes in endothelial cell proliferation but does 
significantly alter endothelial cellular migration. (Komorowski et al., 2006; Tamilarasan et al., 2006) 
 However, almost all of these anti-angiogenic experiments have been performed in human 
culture, mouse, or zebrafish models. This has severely limited their ability to explain the links between 
anti-angiogenic properties and limb deformities in humans. In one of the few studies that was able to 
bridge this gap in knowledge, Therapontos et al. demonstrated that CSP49, an anti-angiogenic analog of 
thalidomide, is able to cause vascular defects prior to changes in FGF8 expression, which is believed to 
be involved in the limb patterning defects (Therapontos, Erskine, Gardner, Figg, & Vargesson, 2009). 
However, this is contrasted by Ito et al which found that zebrafish fin patterning is disrupted prior to 
vascularization of the limb. The applicability of both of these studies to humans is hampered by lack of 
an appropriate mammalian model for thalidomide-induced birth defects. 
Other Teratogenic Outcomes - Other non-mutually exclusive theories have been used to explain 
thalidomide’s teratogenic outcomes, such as the excessive accumulation of reactive oxygen species 
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(ROS). Experiments using spin trapping agents have demonstrated that an overabundance of ROS are 
required for thalidomide to inhibit blood vessel formation (Parman, Wiley, & Wells, 1999). Furthermore, 
there is three times more DNA oxidation in treated rabbits than treated mice (which suggest the role of 
ROS in the species specific nature of thalidomide (Knobloch & Rüther, 2008). 
 In this study we tested the susceptibility of M. domestica development to disruption by 
exposure to thalidomide. To do this we administered thalidomide to pregnant females, and observed 
the resulting impact on gross anatomy, cellular processes including death and proliferation, 
vascularization, and patterns of gene expression. To do this we administered thalidomide to pregnant 
females, and observed the resulting impact on gross anatomy, cellular processes including death and 
proliferation, vascularization, and patterns of gene expression. We hypothesize of the model research 
animals that embryos can easily be obtained, M. domestica best represents the human thalidomide 
phenotype. 
 
METHODS 
Tissue Collection - We maintain a breeding colony with approximately 75 M. domestica with 
detailed pedigrees, at University of Illinois at Urbana Champaign (UIUC). All procedures are in 
accordance with the UIUC IACUC. M. domestica are bred using standard breeding and embryo collection 
protocols (Keyte & Smith, 2008). Mating cages with a single male and female animal are paired and 
infrared video recording used to observe and establish exact mating times. Doses of 500-1000µg of 
thalidomide were dissolved in phosphate buffered saline (PBS) with 1% carboxymethyl cellulose and 1% 
dimethyl sulfoxide (DMSO). This solution or a control solution of similar composition but without 
thalidomide was administered at stage 26 (10.75 hours after mating). Opossums were euthanized via 
carbon dioxide inhalation at time points thereafter, and embryos staged according to (Smith, 2002). 
Skeletal and Vascular Morphology - For the morphology assessments, pregnant opossums were 
euthanized 3 days post treatment with carbon dioxide to effect followed by cervical dislocation. 
Embryos were immediately photographed then fixed in 4% paraformaldehyde in PBS before being 
dehydrated and stored in methanol (MeOH). A single fore- and hindlimb were removed from the 
embryo. The remaining embryo was cleared and stained to visualize the cartilage of the developing 
skeleton using alcian blue (Hanken & Wassersug, 1981). 
Dissected limbs were rehydrated into PBS and washed for 5 hours in Tris-buffered saline (TBS) 
with 1% Triton X-100. To label vasculature, the limbs were then incubated for 48 hours in fetal bovine 
serum with 0.05% dimethyl sulfoxide with Isolectin GS-IB4 from Griffonia simplicifolia, Alexa Fluor® 488 
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Conjugate antibody (Life Technologies). Limbs were counterstained using 40 6-diamidino-2- 
phenylindole (DAPI) (Vectashield Mounting Media with DAPI). Vascularization was quantified by counts 
of distinct branch counts of blood vessels over five 1.25mm2 regions of each labeled using ImageJ. 
Significance was evaluated using a Wilcoxon Rank Sums Test (P threshold=0.05).  
Cell Death and Proliferation - For the cell death and proliferation experiments, 12 hours after 
treatment with either thalidomide or DMSO control [at late stage 27 (11.25 days post mating)] pregnant 
opossums were euthanized as described above. Embryos were fixed in 4% paraformaldehyde in PBS 
before being stored in MeOH. Embryos were then rehydrated into PBS and immersed in 30% sucrose in 
PBS for 12 hours. Tissues were equilibrated in Optimal Cutting Temperature (OCT) compound 
embedding media (Tissue-Tek) for 2 hours then frozen. 10µm sections of the forelimb in the frontal 
plane were taken using a cryotome.  
 Apoptotic cells were visualized using the ApopTag Fluorescein Direct In Situ Apoptosis Detection 
Kit (S7100, Millipore). Three mid limb sections were per embryo from three DMSO treated control 
embryos and three thalidomide treated embryos. Apoptosis was quantified via cell counts of florescent 
cells per overall number of cells in the limb bud. Three sections were sampled per limb and florescence 
counts were repeated three times. Significance was evaluated using Mann-Whitney U Test on the 
proportion of total limb cells fluorescing (P value threshold =.05) 
 Proliferating cells were detected using an antibody against phospho-histone H3 (Ser 10; Cell 
Signaling Technology, 9701). Three mid limb sections were sampled from three DMSO control treated 
embryos and a total of eight mid limb sections were sample from four different thalidomide treated 
embryos. The primary antibody was applied for 24 hours with 1% heat inactivated goat serum and 0.1% 
Triton X-100 in PBS for 12 hours at 4°C. The sections were then washed and incubated with fluorescent 
Alexa Fluor 488 goat anti-rabbit antibody (Invitrogen A31627). Sections were imaged and quantified in 
the same manner as the apoptotic cells. Nuclei were also counterstained using 40 6-diamidino-2- 
phenylindole (DAPI) (Vectashield Mounting Media with DAPI).  
RNA Sequencing - Pregnant opossums were euthanized 30 minutes after treatment at stage 26 
(10.77 hours post mating). Two control and three Thalidomide-treated whole embryos were dissected 
into RNAlater (Ambion) and total RNA extracted using the E.Z.N.A Total RNA Kit 1 (Omega). Single-ended 
RNASeq libraries were made using TruSeq RNA Sample Preparation Kit Version 2 (Illumina). Libraries 
were sequenced by the University Of Illinois Roy G. Carver Biotechnology Center using an Illumina HiSeq 
2500. 
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 The sequence output was processed by removing adapter ends and reads with a Phred score 
below 33 with Trimmomatic Version 0.33 (Bolger, Lohse, & Usadel, 2014). The remaining reads were 
aligned to the M. domestica reference genome using STAR 2.4.0 (Dobin et al., 2013). The monDom5 
assembly and annotation files stored on Ensembl were used (Mikkelsen et al., 2007). EdgeR v3.8.6 was 
used to identify genes that were differentially expressed due to thalidomide treatment (P value 
threshold = 0.01). Gene expression values were normalized as log transformed counts per million 
mapped reads (Robinson, McCarthy, & Smyth, 2010). GO term analysis was performed using v6.7 David 
function annotation tool separately for up and down regulated genes (Huang, Sherman, & Lempicki, 
2008). 
 
RESULTS 
Three major phenotypes are present among the 57 thalidomide-treated embryos that are 
generated by this study. First, the external morphology of 28% (N=16) of the embryos appears normal. 
They are full size, have normal proportions, and do not display any visible deformities. Second, 60% (N = 
34) of embryos display a phenotype that appears mildly affected by thalidomide. These embryos are 
externally normal with exception of the presence of vascular deformities. Third, 12% (N = 7) of embryos 
exhibit a severely affected phenotype that is highly variable in external morphology. 
The mildly deformed embryos occur in all treated litters (Figure 1). These embryos are 
indistinguishable from control embryos in terms of overall size and limb patterning.  Heartbeats can be 
visualized upon removal from the mother. A common defect across these embryos is severe internal 
hemorrhaging, possibly hemangioma(Delahunt & Lassen, 1964). All mildly deformed embryos contain at 
least one area where large amounts of blood have pooled. These areas are located in the limb and areas 
surrounding the base of the forelimb, brain, or abdominopelvic cavity. The placement of these 
hemorrhages are most commonly asymmetrical with the exception the hindlimb which tends to 
hemorrhage symmetrically. The hindlimb is more commonly hemorrhaged than the forelimb, and the 
midbrain is the most commonly affected portion of the head. In four of the embryos the amniotic sac 
was constricted around the embryo just anterior to the hindlimb. These four embryos did not display 
any signs of morphological deformation or size reduction associated with amniotic band syndrome. 
Each of the severely deformed embryos are distinct in morphology. The overall size of these 
embryos is significantly smaller than normal, and is roughly half the size of unaffected or mildly affected 
littermates. All but one of these embryos has no pigmentation in the eye. No significant change is 
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observable in limb vascularization of the zeugopod or autopod between the untreated, mildly affected, 
and severely affected embryos.  
Embryo 1684-1 is the least deformed out of the severely deformed embryos (Figure 2a). Instead 
of a normal single amniotic sac, the amniotic sac has split into two chambers: one surrounding the 
embryo and one connecting to the chorionic plate. The vascular network around the heart is largely 
hemorrhaged. The heart itself is a small mass of improperly organized tissue beneath a single 
membrane, where it should be fully enclosed in the thoracic cavity by this point in development.  While 
the cranial medial portion of the face appears to be normal above the jaw, there is no apparent mouth 
opening and the lateral portions of the cranium are missing or remarkably reduced in size. The length of 
the limb is severely stunted but there are no signs of the phocomelia characteristic of thalidomide. The 
hindlimb appears to be normal and the only notable change to the forelimb is a symmetrical loss of the 
first and fifth digit which results in a narrowed autopod. 
Embryo 699-1 is also one of the milder of the severely deformed embryos (Figure 2B). Like 1684-
1 it has a dual chambered amniotic sac and a large hemorrhage on the ventral surface surrounding the 
heart. The vascular networks appear immature with none of the early establishment of the major blood 
vessels. The medial rostral portion of the face is heavily deformed. The medial portion of the mandibular 
process is severely reduced and the medial nasal process is completely absent. The cranial portion of the 
head also appears to be reduced in size. The cleared and stained specimens show the limbs are normally 
patterned despite the overall size reduction. Like embryo 1684-1, this embryo appears to have been 
viable at least until the point of dissection as demonstrated by the reduction in interdigital tissue and 
protruding tongue characteristic of stage 33 opossums.  
The remaining severely deformed embryos were not clearly alive at the time of dissection as 
they maintain none of the characteristics of stage 33 opossums and did not have blood flow to the 
whole embryo.  Embryo 613-10 appears to have some blood flow though there are no major arteries 
(Figure 2c). The entire rostral portion of the cranium is greatly reduced. The entire section of the 
embryo posterior to the forelimb is reduced in size more than the anterior of the animal. The digits of 
the forelimbs have failed to differentiate and protrude from the embryo at abnormal and asymmetrical 
angles.  
Embryos 627-1 and 627-2 display similar defects (Figure 2d). Though the faces got damaged 
during dissection, a significantly reduced mandibular process is still identifiable. Neither embryo 
contains blood in a visible vascular network. Both hindlimbs are reduced in size and at an immature bud 
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stage. One hindlimb from embryo 627-1 is severely narrowed. The forelimb development of both 
appears to be normal. 
The forelimbs of embryo 1684-2 are normal in their medial-lateral patterning (Figure 2e). They 
are, however, missing a single digit leaving the remaining digits in a symmetrical arrangement. The 
vascular network is incomplete and disorganized. Damage to the head has made cranial identification 
impossible. 
The most disfigured of the embryos is 1684-3 (Figure 2f). It is the smallest embryo collected and 
is less than a third of the length of the healthy embryos. There are only very small patches of blood-filled 
vasculature. The limbs are asymmetrical. The left limb resembles an enlarged version of the limb bud of 
a normal stage 28 opossum. The right limb is severely truncated and reduced in both width and length. 
Much of the cranial morphology is unidentifiable due to gross deformity but the rostral section of the 
head appears to be absent or much reduced. 
Vascular Morphology - No significant changes in vascular morphology has been observed 
between untreated versus mildly affected embryos (P=0.0638) and untreated versus severely affected 
embryos (P=0.8895). Even the limbs of the severely affected embryos appear to have similar level of 
vascular density. However major arteries, such the common carotid and brachial arteries are absent in 
the severely deformed embryos which suggests that there is some disruption of vascular morphology.   
Cell Death Proliferation/Death - The sections of the limb were taken during the enlargement of 
the early limb bud. There was no significant change in the overall number of apoptotic cells (P=0.857) or 
change in the location of cell death. There was also no change in the overall amount of proliferation in 
the limb bud (P=0.889).  The control sample displayed an even distribution of proliferating cells though 
out the entire limb. However the thalidomide treated limbs had minimal proliferation in the center of 
limb (Figure 3). Instead almost all proliferation was localized to the peripheral margins of the bud. There 
was no apparent distinction in proliferation between the distal, anterior or posterior margins of the 
limb.  
Gene Expression Changes - RNAseq analysis identified 1515 significantly upregulated genes and 
1854 significantly down regulated genes from stage 26 Thalidomide treatment. It is worth noting that 
several genes hypothesized to play significant rolls in thalidomide teratogenesis such as FGF2, FGF8, 
FGF10, Gsk3β and Sall4 expression are not significantly differentially expressed in these thalidomide 
treated embryos (Ito et al., 2010; Knobloch & Rüther, 2008; Vargesson, 2013). This does not necessarily 
mean that these genes do not play a role in thalidomide teratogenesis but suggests that they do not do 
so during this specific developmental time window. The angiogenesis GO term is significant at similar 
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levels in both the up- and down- regulated subclasses. The classes of genes that were most strongly 
upregulated were involved in neuron differentiation and embryonic morphogenesis (Table 1). 
Thalidomide syndrome is very similar to the TBX5 defect, Holt-Oram Syndrome, and the two are 
often misdiagnosed for each other (Kohlhase et al., 2003). Interestingly, TBX4 and TBX5, which are 
involved with hind versus fore- limb differentiation, respectively, are both significantly upregulated in 
treated opossums (Table 2).  This is in contrast with other studies that observed a reduction in TBX5 in 
Thalidomide-treated HH stage 23/24 chickens (Knobloch & Rüther, 2008).  
Both MEIS1 and MEIS2 are also significantly upregulated in thalidomide treated limbs. These 
genes are essential for establishing the proximal boundary of the limb (Mercader et al., 1999). 
Additionally MEIS1 mutations display a hemorrhagic phenotype and liver hypoplasia similar to 
phenotypes that result from thalidomide treatment (Azcoitia, Aracil, Martínez-A, & Torres, 2005; 
Gershbein, 1965).  
 More general cell processes such as lipid biosynthesis, steroid metabolism, and transmembrane 
transport were significantly downregulated upon thalidomide exposure (Table 3). Nine of 
downregulated genes were represented in the neuropathy GO term. This is interesting as neuropathy is 
one of the more common side effects of prolonged thalidomide treatment in adults(Efstathiou et al., 
2007).  TIE-2/TEK, an angiopoietin receptor, was found to be essential for vascular network formation 
and was significantly downregulated in thalidomide treated limbs (logFC=-0.769). TIE-2 mutant mice 
display embryonic vascular and patterning deformities which resemble those of thalidomide-treated 
opossums (Sato et al., 1995). TGFBR2 expression was also significantly downregulated in thalidomide 
exposed embryos (logFC=-.719). Similar to the phenotypes generated by thalidomide exposure, TGFBR2 
deficiency can lead to cardiovascular, craniofacial, neurocognitive and skeletal developmental 
abnormalities (Loeys et al., 2005).  
The Apolipoprotein family of genes was found to be significantly downregulated. Not only is this 
gene family significant in hind versus forelimb patterning but it also has been shown to play a major role 
in angiogenesis and hindlimb ischemia (Theurl et al., 2015). Another gene that is downregulated in 
thalidomide treated embryos is Alx4. Alx4 is known to have significant roles in the morphological 
patterning of the limb and functions to pattern the anterior-posterior axis of the limb and ZPA 
restriction (Qu et al., 1997).  
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DISCUSSION 
Embryonic M. domestica that have been exposed to thalidomide replicate most of the 
detectable birth defects associated with human thalidomide teratogenesis and demonstrate potentially 
novel deformities. Thalidomide exposed M. domestica embryos are defective in vascular, face, eye, and 
limb patterning. The lack of significant change in vasculature density may be caused by limitations of the 
assay rather than a lack of vascular malformations.   
Unlike rabbits, affected embryos are very easy to generate, with a 60% penetrance of the mildly 
phenotype and a 12% penetrance of the severe phenotype. This is consistent with human case reports, 
which show that roughly 20% of thalidomide exposed infants were born with severe abnormalities (Lenz 
& Knapp, 1962). Many of the known human genetic pathways of thalidomide teratogenesis appear to be 
maintained in M. domestica. Thalidomide-treated M. domestica also show depleted VEGFA and KDR 
with increased expression of TGFβ. 
This study also represents first full RNA sequencing project that has been performed on any 
thalidomide-treated organism. We have identified several candidate genes involved in thalidomide 
teratogenesis and the partial teratogenic resistance rodents have to the drug. 
With a log fold change of 2.88, SHOX is one of the most significantly upregulated genes found in 
thalidomide-treated opossums. This homeobox gene is located on the X and Y chromosomes and is 
involved in bone growth and maturation, particularly in the limbs. Mutations in SHOX have been linked 
to Turner Syndrome, Langer mesomelic dysplasia, and Léri-Weill dyschondrosteosis (Clement-Jones et 
al., 2000; Rappold et al., 2002). Like thalidomide teratogenesis, all of these disorders are associated with 
greatly reduced limb size. People who suffer from Turner Syndrome and have been exposed to 
thalidomide during their development sometimes also display the same type of abnormally rotated 
joints, known as radial dysplasia. Most interestingly, neither this highly conserved gene nor any ortholog 
of it is present in rodents such as mice, rats and hamsters (Clement-Jones et al., 2000). The potential link 
between rodent resistance to thalidomide limb deformities and SHOX is worth further investigation. 
Another set of genes identified by this study that have gone largely uninvestigated in the 
disruption of limb patterning by thalidomide are the later HOX genes, specifically HOXA11, HOXA13, and 
HOXD11-13. All of these genes are significantly upregulated in treated opossums. One of the major 
functions of this set of genes is to pattern the autopod and the posterior-most region of the embryo 
(Oberg, 2014). In line with this, multiple severely affected opossum embryos exhibit an overall reduction 
in size in their posterior region. Additionally, both opossums and humans that are severely affected by 
thalidomide tend have reduced digits, most commonly the first digit (Lenz & Knapp, 1962). The first digit 
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is believed to be patterned independently of the ZPA by overlapping HOXA13, GLI3R and TBX5 
domains(Oberg, 2014). Establishment of the domain of the first digit is also dependent on the absence 
of HOXD10-12. Interestingly, thalidomide treatment upregulated HOXD12 expression with a log fold 
change of 2.590. This overexpression could contribute to the deletion of the first digit, but further 
analyses are needed to test this hypothesis.  
This is also the first study to identify thalidomide-induced amniotic sac defects. We found 
amniotic sac constrictions both on and separate from the developing embryo after treatment with 
thalidomide. The embryo’s full development inside some of these constrictions suggests that this was a 
fusion of the amniotic sac later in the pregnancy, rather than a patterning defect. Alternatively these 
could represent non-embryonated vesicles. While the cause of these defects is unclear, this could help 
understand some of the less regularly seen thalidomide defects such as the deletion of the distal portion 
of digits. Many of these deformities in humans closely resemble those caused by prenatal constrictions 
in anmniotic band syndrome, so much that the two disorders can be mistaken for each other(Goldfarb, 
Sathienkijkanchai, & Robin, 2009).  
This study is also the first look and cellular proliferation and death in a susceptible mammal 
limb. This lack of change overall proliferation and death change is constant with studies in chick limb 
development(Therapontos et al., 2009).  However the shift in proliferation to the margins of the limb 
bud is not present in chicken models and likely is a better representation of human thalidomide limb 
development.  
 In this study we demonstrate that M. domestica is distinctly well suited to study human 
thalidomide teratogenesis. Most thalidomide induced morphological and gene expression changes are 
conserved from M. domestica to humans. This study has also identified several candidate genes that are 
potentially involved in thalidomide limb patterning disruption. Now that the applicability of this model 
organism has been established, additional research is needed to further evaluate mechanism of 
thalidomide teratogenesis.  
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Go Term % of unregulated 
genes represented 
% of Go Term genes 
represented  
P Value Benjamini 
Neuron Differentiation 7.99 .9 9.3E-33 3.1E-29 
Embryonic Morphogenesis 6.27 .7 7.7E-30 1.3E-26 
Skeletal System 
Development 
5.61 .6 6.3E-22 1.4E-19 
Heart Development 4.16 .5 1.3E-18 1.8E-16 
Blood Vessel Development 3.70 .3 3.4E-11 1.5E-9 
Limb Development 2.18 .2 3.9E-11 1.7E-9 
Table 1: Up Regulated GO Terms 
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Gene Log FC P Value FDR 
ALX3 0.957 0.000566 0.002963 
ALX4 1.295 1.47E-05 0.000123 
APOE -2.558 6.56E-29 9.40E-27 
Ang1 0.812 0.001155 0.005427 
BMP6 -3.604 2.82E-25 2.96E-23 
BMPR2 1.311 3.48E-05 0.00026 
DCC 2.891 6.88E-18 3.49E-16 
GSR -0.789 1.93E-06 1.94E-05 
HAND1 -2.292 5.89E-21 4.08E-19 
HOXA11 1.232 3.59E-07 4.26E-06 
HOXA13 2.241 2.91E-12 7.84E-11 
HOXA4 1.166 3.37E-05 0.000254 
HOXA5 1.115 3.97E-07 4.67E-06 
HOXD12 2.590 2.96E-21 2.17E-19 
HOXD12 2.100 2.93E-14 9.85E-13 
IRX2 0.708 0.000446 0.002435 
IRX4 0.737 0.007207 0.025018 
IRX5 0.816 0.009061 0.030189 
KDR -0.758 3.86E-05 0.000284 
MEIS1 0.818 1.12E-06 1.19E-05 
MEIS2 0.642 6.26E-05 0.000436 
POSTN 3.193 1.95E-28 2.68E-26 
PTGES -4.586 4.33E-51 3.99E-48 
RGCC -3.011 7.79E-46 3.86E-43 
SHH 0.693 0.003237 0.013006 
SHOX 2.884 1.46E-09 2.63E-08 
SHOX2 2.334 3.34E-17 1.58E-15 
SOX9 1.064 2.67E-09 4.54E-08 
ST18 3.053 1.35E-15 5.28E-14 
TBX4 1.913 4.17E-06 3.91E-05 
TBX5 1.147 1.53E-05 0.000127 
TEK -0.769 0.000881 0.004317 
TGFBR2 -1.084 2.63E-06 2.58E-05 
VEGFA -1.945 6.04E-28 8.12E-26 
Table 2: Selected differential expressed gene 
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Go Term % of unregulated genes 
represented 
% of Go Term genes 
represented  
P Value Benjamini 
Organelle Membrane 15.53 1.1 1.3E-30 7.3E-28 
Mitochondria  15.34 1.1 6.2E-30 1.7E-27 
Endoplasmic 
Reticulum 
8.20 .7 5.1E-24 6.0E-22 
Oxidation Reduction 9.28 .7 1.3E-21 5.0E-18 
Lipid Biosynthetic 
Process 
4.90 .4 1.8E-19 3.5E-16 
Response to 
Wounding 
4.41 .3 .022 .31 
Angiogenesis 1.45 .1 .049 .5 
Table 3: Down Regulated GO Terms 
 
